Brief: Novan Inc Exceeds 60% Enrollment Pivotal Phase 3 Study of SB206 For Treatment Of Molluscum
15/12/2020 14:26
Dec 15 (Reuters) - Novan Inc NOVN.O :
* NOVAN INC - EXCEEDED 60% ENROLLMENT IN B-SIMPLE4 PIVOTAL
PHASE 3
STUDY OF SB206 FOR TREATMENT OF MOLLUSCUM
* NOVAN - COMPLETION OF PATIENT ENROLLMENT IN B-SIMPLE4
PIVOTAL
PHASE 3 STUDY TARGETED FOR Q1 2021 WITH READOUT OF TOPLINE
RESULTS TARGETED FOR Q2 2021
Source text for Eikon: ID:nGNX9wJBGk
Further company coverage: NOVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NVN Liquidation
See all newsBrief: Nvn Liquidation Says On April 30, Debtors Filed Notice Of Effective Date With Bankruptcy Court
Brief: Novan Received Notice From Nasdaq Notifying Co's Securities Will Be Delisted From Nasdaq
Brief: Novan Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
U.S. STOCKS ON THE MOVE-Lands' End, Energy sector
U.S. STOCKS ON THE MOVE-Biogen, NetApp, LyondellBasell